SI-BONE, Inc. (NASDAQ:SIBN) Given Consensus Recommendation of “Buy” by Brokerages

SI-BONE, Inc. (NASDAQ:SIBNGet Rating) has been given a consensus rating of “Buy” by the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $34.50.

SIBN has been the topic of several analyst reports. Zacks Investment Research raised shares of SI-BONE from a “sell” rating to a “hold” rating in a report on Wednesday, April 6th. Bank of America reduced their target price on shares of SI-BONE from $43.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, January 18th. Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of SI-BONE in a research note on Monday, January 10th. Cantor Fitzgerald assumed coverage on shares of SI-BONE in a research note on Thursday. They issued an “overweight” rating and a $34.00 target price on the stock. Finally, Truist Financial reduced their target price on shares of SI-BONE from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, December 21st.

SI-BONE stock traded down $0.38 on Monday, hitting $21.43. The company’s stock had a trading volume of 209,544 shares, compared to its average volume of 265,935. The stock has a market capitalization of $717.69 million, a price-to-earnings ratio of -12.61 and a beta of 1.41. The company has a current ratio of 10.41, a quick ratio of 9.73 and a debt-to-equity ratio of 0.26. The firm has a fifty day simple moving average of $20.64. SI-BONE has a one year low of $17.96 and a one year high of $37.21.

SI-BONE (NASDAQ:SIBNGet Rating) last announced its quarterly earnings results on Monday, February 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). The business had revenue of $25.23 million during the quarter. SI-BONE had a negative net margin of 62.75% and a negative return on equity of 38.10%. During the same quarter in the previous year, the business earned ($0.28) earnings per share. On average, analysts predict that SI-BONE will post -1.78 EPS for the current fiscal year.

In other SI-BONE news, SVP Michael A. Pisetsky sold 1,994 shares of the company’s stock in a transaction dated Wednesday, February 16th. The shares were sold at an average price of $20.38, for a total transaction of $40,637.72. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Dunn sold 1,747 shares of the company’s stock in a transaction dated Saturday, January 15th. The shares were sold at an average price of $22.00, for a total transaction of $38,434.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,359 shares of company stock worth $358,333. 7.00% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in SIBN. Maverick Capital Ltd. bought a new stake in shares of SI-BONE in the 3rd quarter valued at about $66,000. Royal Bank of Canada increased its stake in shares of SI-BONE by 52.3% in the 3rd quarter. Royal Bank of Canada now owns 3,913 shares of the company’s stock valued at $83,000 after acquiring an additional 1,343 shares during the last quarter. Citigroup Inc. increased its stake in shares of SI-BONE by 126.1% in the 3rd quarter. Citigroup Inc. now owns 5,515 shares of the company’s stock valued at $118,000 after acquiring an additional 3,076 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of SI-BONE by 393.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,991 shares of the company’s stock valued at $128,000 after acquiring an additional 4,776 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of SI-BONE in the 4th quarter valued at about $204,000.

About SI-BONE (Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Further Reading

Analyst Recommendations for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.